TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04051463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops instilled once daily
Study: NCT00650442
Drug: Estradiol Transdermal System Placebo - Alternate Adhesive
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single application
Study: NCT00650442
Drug: Estradiol Transdermal System Placebo - Current Adhesive
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single application
Study: NCT00531050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose indacaterol matching placebo via Concept 1 device
Study: NCT01280409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
Study: NCT01173471
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral, one tablet once daily, 28 days
Study: NCT01173471
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral 2 tablets twice daily, 28 days
Study: NCT01173471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets, oral, 2 tablets twice daily, 28 days
Study: NCT04397445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet
Study: NCT01429051
Drug: Intranasal Fentanyl Spray (INFS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs
Study: NCT02654171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
Study: NCT02700711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study: NCT03201211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT01856361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill that will match the treatment pill
Study: NCT01299805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching capsules.
Study: NCT01019473
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01019473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01938404
Drug: Standard Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma given as replacement fluid
Study: NCT00933517
Drug: fluorouracile
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 at D1 of each 21-days cycle
Study: NCT00933517
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 at D1 of each 21 dyas cycle
Study: NCT00123955
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg tablet daily for 9 months
Study: NCT00123955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet daily for 9 months
Study: NCT01172821
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that represents BI drug
Study: NCT01172821
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that represents comparator
Study: NCT00692718
Drug: Epadel, Eicosapentaenoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epadel 900mg, 2 times a day, during hospitalization
Study: NCT05301530
Drug: Faceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
Study: NCT01513564
Drug: Local anaesthesia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
Study: NCT00564226
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03561441
Drug: Tailored standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked.
Study: NCT00865618
Drug: Eplerenone 50 mg Tablets Sandoz Inc., USA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00865618
Drug: Inspra 50 mg Tablets GD Searle LLC, USA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02483143
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
Study: NCT02260050
Drug: WAL 801 CL dry syrup new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02260050
Drug: WAL 801 CL dry syrup conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03635957
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral MTX
Study: NCT02579161
Drug: cephalosporins
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
Study: NCT02579161
Drug: Fluoroquinolones
Normalized name: Fluoroquinolones
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
Study: NCT02579161
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
Study: NCT02579161
Drug: Ampicillin/Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
Study: NCT01754116
Drug: GSK1265744 30 mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
Study: NCT00541970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection, different dosing /schedule
Study: NCT03629483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
Study: NCT03635957
Drug: Standard Gout Flare Prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
Study: NCT03042000
Drug: capecitabine with oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combined chemotherapy with capecitabine with oxaliplatin
Study: NCT03107026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT00712426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
Study: NCT03081234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
Study: NCT03081234
Drug: Adjuvant endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
Study: NCT00709839
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
Study: NCT00709839
Drug: Glucose 33%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/kg body weight, intravenous bolus given at time-point 0'
Study: NCT03042000
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single-agent chemotherapy with capecitabine
Study: NCT01660191
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00213083
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04521140
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Study: NCT04521140
Drug: Prednisolone Acetate 1% Oph Susp
Normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection
Study: NCT02514447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01206049
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
Study: NCT02177136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00856830
Drug: Novel Drug Combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks.
Study: NCT04524052
Drug: DWRX2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly injection at pre-defined injection sites
Study: NCT02963376
Drug: 0.05 mL/kg DDFPe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
Study: NCT04524052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly injection at pre-defined injection sites
Study: NCT02563587
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
Study: NCT01452711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
Study: NCT01452711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
Study: NCT03768726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
Study: NCT02963376
Drug: 0.05 mL/kg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
Study: NCT01211704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
Study: NCT00444093
Drug: Opii normata treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day.
Study: NCT04146311
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
Study: NCT04146311
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
Study: NCT01220297
Drug: Cyclophosphamide (Cyclo, CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg
Study: NCT03476525
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are tested for their normal prescription fluoxetine medication
Study: NCT00642577
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study: NCT00642577
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study: NCT01493570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01818908
Drug: DA-EPOCH
Normalized name: Epoch Blemish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH regimen
Study: NCT01721616
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03578029
Drug: RGN-137
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.
Study: NCT03578029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be applied topically to the appropriate wound once a day for up to 84 days.
Study: NCT01782859
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01782859
Drug: Placebo (for Prednisone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04660890
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2050 will be administered orally twice daily as powder-in-capsule.
Study: NCT04660890
Drug: ALXN2050-matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
Study: NCT02072824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
Study: NCT00608517
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02806258
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: minimum of six cycles of PST using anthracycline and/or taxane based regimens
Study: NCT03822507
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02006628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
Study: NCT02006628
Drug: GWP42003
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
Study: NCT02857738
Drug: BAY 987519
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT02857738
Drug: SPF 15 Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT02368431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00912093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of matching placebo
Study: NCT01668550
Drug: AZD0424
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date.
Study: NCT01390311
Drug: Pre-DLI Salvage Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the discretion of the treating physician
Study: NCT02202408
Drug: SKI2670
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, Single Dose
Study: NCT02202408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same shape as the experimental drug
Study: NCT02799030
Drug: BF-200 ALA 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study: NCT02799030
Drug: BF-200 ALA 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .